Medisys buys Lukens Medical for $12.4 million:
This article was originally published in Clinica
Executive Summary
Medisys, the UK-based point-of-care device company, has agreed to pay $12.4 million for Lukens Medical, a wound closure and suture company. Nasdaq-quoted Lukens was founded in 1906 and has recently diversified into sharps disposal and lancets used in diabetes testing. Medisys regards the purchase as a cost-effective way to penetrate the US market. Medisys' diabetes subsidiary Hypoguard has been hit by increased competition and delays in new product launches.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.